



Professor Ruggero Fariello retiring from Newron's Board

Milan, Italy – May 29, 2007 Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that Professor Ruggero Fariello, a non-executive director of the Company, has resigned from his position to pursue other business interests.

Rolf Stahel, Chairman of Newron's Board said: "The Board of Newron thanks Ruggero for his contribution to the Company's development and we wish him well in his future projects."

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide, a unique molecule with multiple mechanisms of action, for the treatment of PD in conjunction with its partner, Merck Serono S.A., which has the rights to develop the compound in PD, Alzheimer's disease, other cognitive disorders and Restless Legs Syndrome. Recent results of a six-month phase III trial of safinamide in PD demonstrated its benefit in motor symptoms and activities of daily living, as well as its improvement in cognitive function, and good tolerability. Newron and Merck Serono are planning to expand the development of safinamide to exploit its potential in Alzheimer's disease. Phase II trials with safinamide in Restless Legs Syndrome have shown promising results. Newron is also conducting phase II trials with ralfinamide for the treatment of neuropathic pain. The drug has potential benefit in inflammatory pain, as well. Newron's clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.

For more information, contact:

Media	Investors and analysts
Italy Luca Benatti - CEO Phone: +39 02 6103 4 626	Stefan Weber - CFO Phone: +39 02 6103 46 30

UK/Global media

Julia Phillips
Financial Dynamics
Phone: +44 (0) 20 7269 7187

Switzerland

Martin Meier-Pfister
The Investor Relations Firm AG
Phone: +41 43 244 81 40

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Newron undertakes no obligation to publicly update or revise any forward-looking statements.